Drug intelligence / Profile preview

TT105

Development stage: Preclinical
Lead developer: Tempo Therapeutics
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Intraarticular

Overview

TT105 is a preclinical-stage microporous annealed particle (MAP) hydrogel biomaterial scaffold developed by Tempo Therapeutics (formerly Tempo Buyer). It is designed as a tissue engineering scaffold to support cartilage repair and regeneration in sports medicine and trauma-related cartilage injuries. Utilizing Tempo's proprietary MAP technology, the injectable biomaterial provides a porous, interconnected microenvironment that promotes cell migration, integration, and tissue regrowth while minimizing inflammation and scarring.

Other names: TT105 - CartilageTT-105 - CartilageTT 105 - Cartilage

Beyond the preview

Go deeper on TT105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT105.

Explore the full profile